Sinovac’s Vaccine Approved by Indonesia for Emergency Use
(Bloomberg) -- Follow Bloomberg on LINE messenger for all the business news and analysis you need.
Indonesia approved China's Sinovac Biotech Ltd. shots for emergency use, paving the way for Southeast Asia's largest economy to start its inoculation program.
The Sinovac vaccine was found to be about 65% effective against Covid-19 in late stage-trials in the city of Bandung, Penny Lukito, head of the food and drug regulator, said in a press briefing Monday. The regulator also considered data from clinical trials in Brazil and Turkey in making the decision, she said.
The vaccine is “largely safe,” Lukito said. “It brings hope of reducing the Covid cases.”
Indonesia to Start Inoculations: Southeast Asia Vaccine Tracker
The emergency use authorization is the first for Sinovac's vaccine outside of China. In Brazil, late stage-trials showed an efficacy rate of 78%. The vaccine was effective in preventing mild cases of the virus and 100% effective against severe and moderate infections, according to the Brazil government.
Indonesia is struggling to rein in the worst coronavirus outbreak in Southeast Asia, with its positivity rate exceeding 31% on Monday in a sign of insufficient testing. The World Health Organization recommends keeping the rate below 5%.
President Joko Widodo is set to receive the first shot on Jan. 13, along with social media influencers and religious leaders. Indonesia needs to boost confidence in the vaccine among its 270 million population to curb the outbreak that has so far infected over 830,000 people.
Indonesia's Ulema Council has declared the Covid-19 vaccines to be halal and clean, and can be used by Muslims in line with guidelines from relevant authorities. Sinovac has shipped 3 million doses to the country, which plans to inoculate 181.5 million people by March 2022.
©2021 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
